For many patients with autoimmune hepatitis (AIH), the presence of extrahepatic features is well recognised both at the time of presentation and during long-term follow-up. Concomitant ‘autoimmune disorders' have been described in 20-50% of patients with AIH, both in adults and children. Indeed, the presence of these associated phenomena has been incorporated into both the original and revised International AIH group scoring systems as an aid to codifying the diagnosis. In acute index presentations, non-specific joint pains sometimes flitting in nature have been reported in 10-60% of patients, and while joint swelling is uncommon, rheumatoid arthritis and mixed connective tissue disease have been reported in 2-4% of patients with AIH. For a majority of patients, these joint symptoms resolve within days of the introduction of immunosuppressive therapy. Rarer features at index presentation include a maculopapular skin rash and unexplained fever, which are features that tend to resolve quickly with treatment. Interestingly, joint pain and stiffness are also well recognised in the context of steroid withdrawal and cessation in AIH. The occasional co-presentation of AIH with coeliac disease is clinically important (1-6%), since for some patients, there is a risk of immunosuppression malabsorption, thus delaying effective treatment. Similarly, the co-existence of selective IgA deficiency (IgAD) can occur in patients with coeliac disease or in isolation. Selective IgAD as a co-existing extraheaptic feature seems to be more common in paediatric patients with AIH. For these patients, they are at an increased risk of respiratory and sinus infections. Although, typically associated with primary sclerosing cholangitis, the presence of inflammatory bowel disease (IBD; both Crohn's disease and ulcerative colitis) has been described in 2-8% of patients with AIH. Interestingly, for patients with autoimmune sclerosing cholangitis, a distinct pattern of IBD has been recently described. Other conditions have been reported at a lower frequency, including Sjogren's syndrome 1-7%, systemic lupus erythematosus 1-3% and glomerulonephritis 1%. Rarer still and at a frequency of <1% include fibrosing alveolitis, haemolytic anaemia, uveitis, mononeuritis multiplex, polymyositis and multiple sclerosis. In contrast, the reported associations between AIH and thyroiditis 8-23%, diabetes 1-10% and psoriasis 3% are commonly seen and notable in clinical practice.

Krawitt EL: Autoimmune hepatitis. N Engl J Med 2006;354:54-66.
Gleeson D, Heneghan MA; British Society of Gastroenterology: British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011;60:1611-1629.
McFarlane IG, Heneghan MA: Autoimmunity and the female liver. Hepatol Res 2004;28:171-176.
Read AE, Sherlock S, Harrison CV: Active ‘juvenile' cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 1963;4:378-393.
Mistilis SP, Blackburn CR: Active chronic hepatitis. Am J Med 1970;48:484-495.
Golding PL, Smith M, Williams R: Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med 1973;55:772-782.
Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, et al: Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010;44:208-213.
Werner M, Prytz H, Ohlsson B, Almer S, Björnsson E, Bergquist A, et al: Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study. Scand J Gastroenterol 2008;43:1232-1240.
Van Gerven NM, Verwer BJ, Witte BI, van Erpecum KJ, van Buuren HR, Maijers I, et al; Dutch Autoimmune hepatitis STUDY group: Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol 2014;49:1245-1254.
Muratori P, Czaja AJ, Muratori L, Pappas G, Maccariello S, Cassani F, et al: Genetic distinctions between autoimmune hepatitis in Italy and North America. World J Gastroenterol 2005;11:1862-1866.
Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, et al: Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment Pharmacol Ther 2006;24:1051-1057.
Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA: Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006;45:575-583.
Miyake Y, Iwasaki Y, Takaki A, Kobashi H, Sakaguchi K, Shiratori Y: Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis. Intern Med 2007;46:1945-1949.
Abe M, Mashiba T, Zeniya M, Yamamoto K, Onji M, Tsubouchi H, et al; Autoimmune Hepatitis Study Group-Subgroup of the Intractable Hepato-Biliary Disease Study Group in Japan: Present status of autoimmune hepatitis in Japan: a nationwide survey. J Gastroenterol 2011;46:1136-1141.
Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al: Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-547.
Choudhuri G, Somani SK, Baba CS, Alexander G: Autoimmune hepatitis in India: profile of an uncommon disease. BMC Gastroenterol 2005;5:27.
Peng M, Li Y, Zhang M, Jiang Y, Xu Y, Tian Y, et al: Clinical features in different age groups of patients with autoimmune hepatitis. Exp Ther Med 2014;7:145-148.
Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al: Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of ‘autoimmune' hepatitis. Hepatology 1987;7:1333-1339.
Bittencourt PL, Farias AQ, Porta G, Cançado EL, Miura I, Pugliese R, et al: Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008;42:300-305.
Johnson PJ, McFarlane IG: Meeting report: international autoimmune hepatitis group. Hepatology 1993;18:998-1005.
Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al: International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
Vázquez-García MN, Aláez C, Olivo A, Debaz H, Pérez-Luque E, Burguete A, et al: MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol 1998;28:985-990.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB: Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993;18:816-822.
Marcos Y, Fainboim HA, Capucchio M, Findor J, Daruich J, Reyes B, et al: Two-locus involvement in the association of human leukocyte antigen with the extrahepatic manifestations of autoimmune chronic active hepatitis. Hepatology 1994;19:1371-1374.
Czaja AJ, Donaldson PT: Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:2051-2057.
Tanriverdi F, Silveira LF, MacColl GS, Bouloux PM: The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003;176:293-304.
Al-Chalabi T, Underhill JA, Portmann BC, McFarlane IG, Heneghan MA: Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. J Hepatol 2008;48:140-147.
Tait B, Mackay IR, Board P, Coggan M, Emery P, Eckardt G: HLA A1, B8, DR3 extended haplotypes in autoimmune chronic hepatitis. Gastroenterology 1989;97:479-481.
Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R: Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991;13:701-706.
Badenhoop K, Schwarz G, Walfish PG, Drummond V, Usadel KH, Bottazzo GF: Susceptibility to thyroid autoimmune disease: molecular analysis of HLA-D region genes identifies new markers for goitrous Hashimoto's thyroiditis. J Clin Endocrinol Metab 1990;71:1131-1137.
Tandon N, Zhang L, Weetman AP: HLA associations with Hashimoto's thyroiditis. Clin Endocrinol (Oxf) 1991;34:383-386.
Grennan DM, Sanders PA, Thomson W, Dyer PA: Rheumatoid arthritis: inheritance and association with other autoimmune diseases. Dis Markers 1986;4:157-162.
Van Heemst J, van der Woude D, Huizinga TW, Toes RE: HLA and rheumatoid arthritis: how do they connect? Ann Med 2014;46:304-310.
Moutsopoulos HM, Mann DL, Johnson AH, Chused TM: Genetic differences between primary and secondary sicca syndrome. N Engl J Med 1979;301:761-763.
Toyoda H, Wang SJ, Yang HY, Redford A, Magalong D, Tyan D, et al: Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 1993;104:741-748.
Asakura H, Tsuchiya M, Aiso S, Watanabe M, Kobayashi K, Hibi T, et al: Association of the human lymphocyte-DR2 antigen with Japanese ulcerative colitis. Gastroenterology 1982;82:413-418.
Payami H, Khan MH, Grennan DM, Sanders PA, Dyer PA, Thomson G: Analysis of genetic interrelationship among HLA-associated diseases. Am J Hum Genet 1987;41:331-349.
Howell WM: HLA and disease: guilt by association. Int J Immunogenet 2014;41:1-12.
Czaja AJ, Souto EO, Bittencourt PL, Cancado ELR, Porta G, Goldberg AC, et al: Clinical distinctions and pathogenic implications of type-1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-308.
De Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al: Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-452.
Sacher M, Blümel P, Thaler H, Manns M: Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990;10:364-369.
Wat H, Haber RM: Trends in the association between pyoderma gangrenosum and autoimmune hepatitis: case report and review of the literature. J Cutan Med Surg 2014;18:345-352.
Halac U, Al Dhaybi R, Powell J, Bouron-Dal Soglio D, Alvarez F: Unusual association between autoimmune hepatitis and severe pyoderma gangrenosum. J Pediatr Gastroenterol Nutr 2010;50:219-221.
Biró E, Szekanecz Z, Czirják L, Dankó K, Kiss E, Szabó NA, et al: Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006;25:240-245.
Granito A, Muratori L, Pappas G, Muratori P, Ferri S, Cassani F, et al: Clinical features of type 1 autoimmune hepatitis in elderly Italian patients. Aliment Pharmacol Ther 2005;21:1273-1277.
Saich R, Chapman R: Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease. World J Gastroenterol 2008;14:331-337.
Perdigoto R, Carpenter HA, Czaja AJ: Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992;14:325-331.
Ordonez F, Lacaille F, Canioni D, Talbotec C, Fournet JC, Cerf-Bensussan N, et al: Pediatric ulcerative colitis associated with autoimmune diseases: a distinct form of inflammatory bowel disease? Inflamm Bowel Dis 2012;18:1809-1817.
Panetta F, Nobili V, Sartorelli MR, Papa RE, Ferretti F, Alterio A, et al: Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management. Paediatr Drugs 2012;14:35-41.
Lindberg J, Ahrén C, Iwarson S: Intestinal villous atrophy in chronic active hepatitis. Scand J Gastroenterol 1979;14:1015-1018.
Swarbrick ET, Fairclough PD, Campbell PJ, Levison DA, Greenwood RH, Baker LR: Coeliac disease, chronic active hepatiti, and mesangiocapillary glomerulonephritis in the same patient. Lancet 1980;2:1084-1085.
Mirzaagha F, Azali SH, Islami F, Zamani F, Khalilipour E, Khatibian M, et al: Coeliac disease in autoimmune liver disease: a cross-sectional study and a systematic review. Dig Liver Dis 2010;42:620-623.
Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M, et al: Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis. Dig Dis Sci 1998;43:2190-2195.
Villalta D, Girolami E, Alessio MG, Sorrentino MC, Tampoia M, Brusca I, et al; on behalf of the Study Group on Autoimmune Diseases of the Italian Society of Laboratory Medicine, Italy: Autoantibody profiling in a cohort of pediatric and adult patients with autoimmune hepatitis. J Clin Lab Anal 2014, Epub ahead of print.
Van Gerven NM, Bakker SF, de Boer YS, Witte BI, Bontkes H, van Nieuwkerk CM, et al; Dutch AIH working group: Seroprevalence of celiac disease in patients with autoimmune hepatitis. Eur J Gastroenterol Hepatol 2014;26:1104-1107.
Vajro P, Paolella G, Maggiore G, Giordano G: Pediatric celiac disease, cryptogenic hypertransaminasemia, and autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2013;56:663-670.
Nastasio S, Sciveres M, Riva S, Filippeschi IP, Vajro P, Maggiore G: Celiac disease-associated autoimmune hepatitis in childhood: long-term response to treatment. J Pediatr Gastroenterol Nutr 2013;56:671-674.
Wang N, Hammarström L: IgA deficiency: what is new? Curr Opin Allergy Clin Immunol 2012;12:602-608.
Wang N, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, et al: Selective IgA deficiency in autoimmune diseases. Mol Med 2011;17:1383-1396.
Chow MA, Lebwohl B, Reilly NR, Green PH: Immunoglobulin A deficiency in celiac disease. J Clin Gastroenterol 2012;46:850-854.
Duchini A, McHutchison JG, Pockros PJ: LKM-positive autoimmune hepatitis in the western United States: a case series. Am J Gastroenterol 2000;95:3238-3241.
Yel L: Selective IgA deficiency. J Clin Immunol 2010;30:10-16.
Van Thiel DH, Finkel R, Friedlander L, Gavaler JS, Wright HI, Gordon R: The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation. Transplantation 1992;54:269-273.
Quintin E, Scoazec JY, Marotte H, Miossec P: Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes. Arthritis Res Ther 2010;12:R143.
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, et al; USA PBC Epidemiology Group: Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005;42:1194-1202.
Matsumoto T, Morizane T, Aoki Y, Yamasaki S, Nakajima M, Enomoto N, et al: Autoimmune hepatitis in primary Sjogren's syndrome: pathological study of the livers and labial salivary glands in 17 patients with primary Sjogren's syndrome. Pathol Int 2005;55:70-76.
Runyon BA, LaBrecque DR, Anuras S: The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med 1980;69:187-194.
Efe C, Purnak T, Ozaslan E, Ozbalkan Z, Karaaslan Y, Altiparmak E, et al: Autoimmune liver disease in patients with systemic lupus erythematosus: a retrospective analysis of 147 cases. Scand J Gastroenterol 2011;46:732-737.
Beisel C, Weiler-Normann C, Teufel A, Lohse AW: Association of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature. World J Gastroenterol 2014;20:12662-12667.
Tojo J, Ohira H, Abe K, Yokokawa J, Takiguchi J, Rai T, et al: Autoimmune hepatitis accompanied by systemic lupus erythematosus. Intern Med 2004;43:258-262.
Tomsic M, Ferlan-Marolt V, Kveder T, Hojker S, Rozman B: Mixed connective tissue disease associated with autoimmune hepatitis and thyroiditis. Ann Rheum Dis 1992;51:544-546.
Marshall JB, Ravendhran N, Sharp GC: Liver disease in mixed connective tissue disease. Arch Intern Med 1983;143:1817-1818.
Rolny P, Goobar J, Zettergren L: HBsAg-negative chronic active hepatitis and mixed connective tissue disease syndrome. An unusual association observed in two patients. Acta Med Scand 1984;215:391-395.
Maeda M, Kanayama M, Hasumura Y, Takeuchi J, Uchida T: Case of mixed connective tissue disease associated with autoimmune hepatitis. Dig Dis Sci 1988;33:1487-1490.
Wada T, Motoo Y, Ohmizo R, Terada T, Nakanuma Y: Association of mixed connective tissue disease, Sjögren's syndrome and autoimmune hepatitis: report of a case. Jpn J Med 1991;30:278-280.
Marie I, Levesque H, Tranvouez JL, François A, Riachi G, Cailleux N, et al: Autoimmune hepatitis and systemic sclerosis: a new overlap syndrome? Rheumatology (Oxford) 2001;40:102-106.
Pamfil C, Candrea E, Berki E, Popov HI, Radu PI, Rednic S: Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome associated with dermatomyositis, autoimmune thyroiditis and antiphospholipid syndrome. J Gastrointestin Liver Dis 2015;24:101-104.
Uthman I, Khamashta M: The abdominal manifestations of the antiphospholipid syndrome. Rheumatology (Oxford) 2007;46:1641-1647.
Paul K, Wille L, Feist D, Kayser K: [Fibrosing alveolitis in a 7-year-old girl with autoimmune hemolytic anemia and autoimmune hepatitis]. Pneumologie 1991;45:928-931.
Williams AJ, Marsh J, Stableforth DE: Cryptogenic fibrosing alveolitis, chronic active hepatitis and autoimmune haemolytic anaemia in the same patient. Br J Dis Chest 1985;79:200-203.
Luth S, Birklein F, Schramm C, Herkel J, Hennes E, Muller-Forell W, et al: Multiplex neuritis in a patient with autoimmune hepatitis: a case report. World J Gastroenterol 2006;12:5396-5398.
Ko KF, Ho T, Chan KW: Autoimmune chronic active hepatitis and polymyositis in a patient with myasthenia gravis and thymoma. J Neurol Neurosurg Psychiatry 1995;59:558-559.
Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, et al: Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997;82:1353-1361.
Chuang E, Ruchelli E, Mulberg AE: Autoimmune liver disease and sickle cell anemia in children: a report of three cases. J Pediatr Hematol Oncol 1997;19:159-162.
el Younis CM, Min AD, Fiel MI, Klion FM, Thung SN, Faire B, et al: Autoimmune hepatitis in a patient with sickle cell disease. Am J Gastroenterol 1996;91:1016-1018.
Bloom JN, Rabinowicz IM, Shulman ST: Uveitis complicating autoimmune chronic active hepatitis. Am J Dis Child 1983;137:1175-1176.
Lim LL, Scarborough JD, Thorne JE, Graham E, Kempen JH, Mackensen F, et al: Uveitis in patients with autoimmune hepatitis. Am J Ophthalmol 2009;147:332-338.e1.
Kaplan MM: Primary biliary cirrhosis. N Engl J Med 1996;335:1570-1580.
Koulentaki M, Ioannidou D, Stefanidou M, Maraki S, Drigiannakis I, Dimoulios P, et al: Dermatological manifestations in primary biliary cirrhosis patients: a case control study. Am J Gastroenterol 2006;101:541-546.
Newton JL, Hollingsworth KG, Taylor R, El-Sharkawy AM, Khan ZU, Pearce R, et al: Cognitive impairment in primary biliary cirrhosis: symptom impact and potential etiology. Hepatology 2008;48:541-549.
Wang L, Zhang FC, Chen H, Zhang X, Xu D, Li YZ, et al: Connective tissue diseases in primary biliary cirrhosis: a population-based cohort study. World J Gastroenterol 2013;19:5131-5137.
Tsianos EV, Hoofnagle JH, Fox PC, Alspaugh M, Jones EA, Schafer DF, et al: Sjögren's syndrome in patients with primary biliary cirrhosis. Hepatology 1990;11:730-734.
Ueno Y, Shibata M, Onozuka Y: [Association of extrahepatic autoimmune diseases in primary biliary cirrhosis - clinical statistics and analyses of Japanese and non-Japanese cases]. Nihon Rinsho 1998;56:2687-2698.
Liu B, Zhang FC, Zhang ZL, Zhang W, Gao LX: Interstitial lung disease and Sjögren's syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol 2008;27:1299-1306.
Mantaka A, Koulentaki M, Chlouverakis G, Enele-Melono JM, Darivianaki A, Tzardi M, et al: Primary biliary cirrhosis in a genetically homogeneous population: disease associations and familial occurrence rates. BMC Gastroenterol 2012;12:110.
Uddenfeldt P, Danielsson A, Forssell A, Holm M, Ostberg Y: Features of Sjögren's syndrome in patients with primary biliary cirrhosis. J Intern Med 1991;230:443-448.
Watt FE, James OF, Jones DE: Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study. QJM 2004;97:397-406.
Floreani A, Franceschet I, Cazzagon N, Spinazzè A, Buja A, Furlan P, et al: Extrahepatic autoimmune conditions associated with primary biliary cirrhosis. Clin Rev Allergy Immunol 2015;48:192-197.
Gillett HR, Cauch-Dudek K, Jenny E, Heathcote EJ, Freeman HJ: Prevalence of IgA antibodies to endomysium and tissue transglutaminase in primary biliary cirrhosis. Can J Gastroenterol 2000;14:672-675.
Kingham JG, Parker DR: The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences. Gut 1998;42:120-122.
Floreani A, Spinazzè A, Caballeria L, Reig A, Cazzagon N, Franceschet I, et al: Extrahepatic malignancies in primary biliary cirrhosis: a comparative study at two European centers. Clin Rev Allergy Immunol 2015;48:254-262.
Lee YM, Kaplan MM: Primary sclerosing cholangitis. N Engl J Med 1995;332:924-933.
Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, et al: Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987;22:655-664.
Yimam KK, Bowlus CL: Diagnosis and classification of primary sclerosing cholangitis. Autoimmun Rev 2014;13:445-450.
Loftus EV Jr, Sandborn WJ, Lindor KD, Larusso NF: Interactions between chronic liver disease and inflammatory bowel disease. Inflamm Bowel Dis 1997;3:288-302.
Loftus EV Jr, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, et al: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005;54:91-96.
Heuschen UA, Hinz U, Allemeyer EH, Stern J, Lucas M, Autschbach F, et al: Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology 2001;120:841-847.
Penna C, Dozois R, Tremaine W, Sandborn W, LaRusso N, Schleck C, et al: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut 1996;38:234-239.
Lamberts LE, Janse M, Haagsma EB, van den Berg AP, Weersma RK: Immune-mediated diseases in primary sclerosing cholangitis. Dig Liver Dis 2011;43:802-806.
Saarinen S, Olerup O, Broomé U: Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol 2000;95:3195-3199.
Ngu JH, Gearry RB, Frampton CM, Stedman CA: Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012;55:522-529.
Schrumpf E, Abdelnoor M, Fausa O, Elgjo K, Jenssen E, Kolmannskog F: Risk factors in primary sclerosing cholangitis. J Hepatol 1994;21:1061-1066.
Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, et al: Celiac disease in autoimmune cholestatic liver disorders. Am J Gastroenterol 2002;97:2609-2613.
Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.
Floreani A, Liberal R, Vergani D, Mieli-Vergani G: Autoimmune hepatitis: contrasts and comparisons in children and adults - a comprehensive review. J Autoimmun 2013;46:7-16.
Tufano M, Della Corte C, Cirillo F, Spagnuolo MI, Candusso M, Melis D, et al: Fulminant autoimmune hepatitis in a girl with 22q13 deletion syndrome: a previously unreported association. Eur J Pediatr 2009;168:225-227.
Lankisch TO, Jaeckel E, Strassburg CP: The autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome type 1. Semin Liver Dis 2009;29:307-314.
Czaja AJ: Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008;7:319-333.
Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al; American Association for the Study of Liver Diseases: Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH: Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in the Netherlands. Am J Gastroenterol 1999;94:2417-2422.
Maddocks JL, Lennard L, Amess J, Amos R, Thomas RM: Azathioprine and severe bone marrow depression. Lancet 1986;1:156.
Ben Ari Z, Mehta A, Lennard L, Burroughs AK: Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-354.
Wang KK, Czaja AJ, Beaver SJ, Go VL: Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989;10:39-43.
Czaja AJ, Carpenter HA: Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-975.
Ziegler TR, Fernández-Estívariz C, Gu LH, Fried MW, Leader LM: Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 2003;124:1950-1957.
Leung J, Dowling L, Obadan I, Davis J, Bonis PA, Kaplan MM, et al: Risk of non-melanoma skin cancer in autoimmune hepatitis. Dig Dis Sci 2010;55:3218-3223.
Werner M, Almer S, Prytz H, Lindgren S, Wallerstedt S, Björnsson E, et al: Hepatic and extrahepatic malignancies in autoimmune hepatitis. A long-term follow-up in 473 Swedish patients. J Hepatol 2009;50:388-393.
Johnson PJ, McFarlane IG, Williams R: Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-963.
Zold E, Bodolay E, Dezső B, Soos G, Nakken B, Szodoray P: Mixed connective tissue disease associated with autoimmune hepatitis and pulmonary fibrosis. Isr Med Assoc J 2014;16:733-734.
Czaja AJ: Autoimmune liver disease and rheumatic manifestations. Curr Opin Rheumatol 2007;19:74-80.
Silveira MG, Mendes FD, Diehl NN, Enders FT, Lindor KD: Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease. Liver Int 2009;29:1094-1100.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.